| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | E3 SUMO-protein ligase PIAS1;6.3.2.-;DEAD/H box-binding protein 1;Gu-binding protein;GBP;Protein inhibitor of activated STAT protein 1;RNA helicase II-binding protein;PIAS1;DDXBP1; |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Form | Liquid |
| Host | |
| Immunogen | A synthesized peptide derived from human PIAS1 |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Storage | |
| Target | |
| UniProt # |
Overview
This product is an anti-PIAS1 antibody for target detection and characterization. Key identifiers include host species: Rabbit; Monoclonal; clone 19P34; isotype IgG; reactivity: Human,Mouse,Rat. Reported application contexts include WB, IHC, ICC, IF, Flow (as provided in the source record). Boster Bio Anti-PIAS1 Rabbit Monoclonal Antibody catalog # M01707-1. Tested in WB, IHC, ICC/IF, Flow Cytometry applications. This antibody reacts with Human, Mouse, Rat.
Key elements and design rationale
- Target: PIAS1 (E3 SUMO-protein ligase PIAS1).
- Antibody format: Monoclonal; clone 19P34; isotype IgG.
- Host: Rabbit.
- Species reactivity: Human,Mouse,Rat (confirm in your model system with appropriate controls).
This description is intended to help interpret the antibody design and the biological context of the target using the fields provided in the catalog record, alongside general experimental considerations.
Biological background
PIAS1 (protein: Lysosome-associated membrane glycoprotein 2 (Lamp2)) is a commonly studied target in molecular and cellular biology. Functional context (as provided): Functions as an E3-type small ubiquitin-like modifier (SUMO) ligase, stabilizing the interaction between UBE2I and the substrate, and as a SUMO-tethering factor. Plays a crucial role as a transcriptional coregulation in various cellular pathways, including the STAT pathway, the p53 pathway and the steroid hormone signaling pathway. In vitro, binds A/T-rich DNA. The effects of this transcriptional coregulation, transactivation or silencing, may vary depending upon the biological context. Together with PRMT1, may repress STAT1 transcriptional activity, in the late phase of interferon gamma (IFN-gamma) signaling. Sumoylates PML (at'Lys-65' and 'Lys-160') and PML-RAR and promotes their ubiquitin-mediated degradation. PIAS1-mediated sumoylation of PML promotes its interaction with CSNK2A1/CK2 which in turn promotes PML phosphorylation and degradation (By similarity). Enhances the sumoylation of MTA1 and may participate in its paralog-selective sumoylation. Plays a dynamic role in adipogenesis by promoting the SUMOylation and degradation of CEBPB (By similarity). . Reported cellular localization context: Nucleus speckle . Nucleus, PML body . Interaction with CSRP2 may induce a partial redistribution along the cytoskeleton. Tissue expression notes (as provided): Expressed in numerous tissues with highest level in testis. .
Research relevance and current trends
- Research context keywords from the source record include: 2339,Co-Activators/Co-Repressors,Epigenetics and Nuclear Signaling,Nuclear Receptors,Nuclear Signaling Pathways,Transcription,Ubiquitin & Ubiquitin Like Modifiers.
- Current studies often focus on connecting target abundance/localization to pathway perturbations across models, tissues, and cell states.
- Quantitative and multiplexed assays (e.g., imaging + immunoblot panels) are commonly used to compare phenotypes across conditions and time-courses.
Common research applications
- Western blotting (WB): assess relative target abundance across samples, treatments, or time-points.
- Immunohistochemistry (IHC): evaluate spatial distribution of target-positive staining in tissue architecture.
- Immunofluorescence/ICC (IF/ICC): visualize subcellular localization patterns and cell-to-cell heterogeneity.
- Flow cytometry: quantify target-positive populations and compare shifts in marker distributions.
Workflow ideas (metafield): Validate PIAS1 antibody specificity using KO/KD control samples (WB/IF/IHC as appropriate), Detect PIAS1 expression by Western blot in cell or tissue lysates, Detect PIAS1 in FFPE tissue sections by immunohistochemistry, Localize PIAS1 by immunofluorescence/immunocytochemistry in cultured cells, Quantify PIAS1-positive cells by flow cytometry in single-cell suspensions
Notes for experimental interpretation
- Consider isoforms and post-translational modifications (PTMs) that may shift apparent molecular weight or epitope accessibility.
- Apparent molecular weight may vary by sample type and processing (observed MW: 72 kDa; calculated MW: 71836 MW).
- Control concepts: include appropriate negative controls (e.g., isotype, KO/KD samples) and orthogonal validation when feasible.
Additional product details (from the source record)
- Molecular weight (observed): 72 kDa
- Cellular localization (provided): Nucleus speckle . Nucleus, PML body . Interaction with CSRP2 may induce a partial redistribution along the cytoskeleton.
- Tissue details (provided): Expressed in numerous tissues with highest level in testis. .
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
